Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Champions Oncology (CSBR) Return on Capital Employed (2016 - 2026)

Champions Oncology has reported Return on Capital Employed over the past 16 years, most recently at 30.43% for Q1 2026.

  • For Q1 2026, Return on Capital Employed fell 10842.0% year-over-year to 30.43%; the TTM value through Jan 2026 reached 30.43%, down 10842.0%, while the annual FY2025 figure was 84.55%, 16929.0% up from the prior year.
  • Return on Capital Employed for Q1 2026 was 30.43% at Champions Oncology, down from 26.18% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 77.99% in Q1 2025 and troughed at 172.4% in Q1 2024.
  • A 5-year average of 26.74% and a median of 12.64% in 2024 define the central range for Return on Capital Employed.
  • Biggest five-year swings in Return on Capital Employed: tumbled -15269bps in 2024 and later surged 25039bps in 2025.
  • Year by year, Return on Capital Employed stood at 1.45% in 2022, then plummeted by -8104bps to 116.39% in 2023, then soared by 89bps to 12.64% in 2024, then surged by 307bps to 26.18% in 2025, then plummeted by -216bps to 30.43% in 2026.
  • Business Quant data shows Return on Capital Employed for CSBR at 30.43% in Q1 2026, 26.18% in Q4 2025, and 30.83% in Q3 2025.